Quick Answer
Translational Development Acquisition Corp. reported Operating Income Loss of -$944.5 thousand for the year ending 2025.
- Translational Development Acquisition Corp. showed a decrease of -381.0% in Operating Income Loss from 2024 to 2025.
- This data is from Translational Development Acquisition Corp.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $0.00 | Q2 2024: -$1.7 thousand | Q3 2024: -$61.3 thousand | Q1 2025: -$347.4 thousand | Q2 2025: -$221.1 thousand | Q3 2025: -$213.7 thousand.
- Over the full 3 years of available data (2023 to 2025), Translational Development Acquisition Corp.'s Operating Income Loss has declined by 94.5%.
- Historical annual values: Fiscal year 2025: -$944.5 thousand | Fiscal year 2024: -$196.4 thousand | Fiscal year 2023: -$485.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: